Sparsentan, a dual inhibitor of the angiotensin II type 1 (AT1) receptor and ETA-R that demonstrated significant reduction in proteinuria compared to irbesartan in patients with focal segmental glomerulosclerosis (FSGS) [104] is currently being tested in the phase III PROTECT trial (ClinicalTrials.gov Identifier: NCT03762850) evaluating its long-term renoprotective potential in IgAN. The gene discussed is EDNRA; the disease is focal segmental glomerulosclerosis.